Early Targeted Combination Treatment With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs and Long‐Term Outcomes in Rheumatoid Arthritis: Ten‐Year Follow‐Up Results of a Randomized Clinical Trial
- 29 October 2019
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 71 (11) , 1450-1458
Abstract
Objective: The short‐term outcomes of remission‐targeted treatments of rheumatoid arthritis (RA) are well‐established, but the long‐term success of such strategies is speculative, as is the role of early add‐on biologics. We assessed the 10‐year outcomes of patients with early RA treated with initial remission‐targeted triple combination of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), 7.5‐mg prednisolone, and additional infliximab (IFX) or placebo infusions.Methods: Ninety‐nine patients with early, DMARD‐naive RA were treated with a triple combination of csDMARDs and prednisolone and randomized to double‐blind receipt of infusions of either IFX (the Finnish Rheumatoid Arthritis Combination Therapy Trial [FIN‐RACo] + IFX) or placebo (FIN‐RACo + placebo) during the first 6 months. After 2 years, the treatment strategies became unrestricted, but the treatment goal was strict remission in the TNF‐Blocking Therapy in Combination With Disease‐Modifying Antirheumatic Drugs in Early Rheumatoid Arthritis (NEO‐RACo) study. At 10 years, the clinical and radiographic outcomes and the drug treatments used between 5 and 10 years were assessed.Results: Ninety patients (91%) were followed after 2 years, 43 in the FIN‐RACo + IFX and 47 in the FIN‐RACo + placebo group. At 10 years, the respective proportions of patients in strict NEO‐RACo remission and in Disease Activity Score using 28 joints remission in the FIN‐RACo + IFX and FIN‐RACo + placebo groups were 46% and 38% (P = 0.46) and 82% and 72% (P = 0.29), respectively. The mean total Sharp/van der Heijde score was 9.8 in the FIN‐RACo + IFX and 7.3 in the FIN‐RACo + placebo group (P = 0.34). During the 10‐year follow‐up, 26% of the FIN‐RACo + IFX group and 30% of the FIN‐RACo + placebo group had received biologics (P = 0.74).Conclusion: In early RA, excellent results can be maintained up until 10 years in most patients treated with initial combination csDMARDs and remission‐targeted strategy, regardless of initial IFX/placebo infusions.Keywords
This publication has 20 references indexed in Scilit:
- Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trialAnnals of the Rheumatic Diseases, 2014
- What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature reviewAnnals of the Rheumatic Diseases, 2014
- Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)Annals of the Rheumatic Diseases, 2013
- Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic TherapyJAMA, 2012
- Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trialArthritis Research & Therapy, 2010
- Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 2010
- The good initial response to therapy with a combination of traditional disease‐modifying antirheumatic drugs is sustained over time: The eleven‐year results of the Finnish rheumatoid arthritis combination therapy trialArthritis & Rheumatism, 2009
- Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective studyArthritis Research & Therapy, 2008
- Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988